Navigation Links
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:10/31/2008

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed

Following a Rituximab-Containing Regimen

FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The data supporting the FDA approval show that TREANDA is effective, has a tolerable side effect profile in patients with indolent NHL and that treatment results in a high durable response rate. In March of this year, TREANDA received approval for the treatment of patients with chronic lymphocytic leukemia, the most common form of leukemia in the United States.

Indolent NHL, a subset of non-Hodgkin's lymphoma, is a slow growing but serious cancer of the lymphatic system that is not curable with currently available treatments. Patients with indolent NHL are prone to multiple relapses after initial therapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed this year with indolent NHL.

"Because most patients with indolent non-Hodgkin's lymphoma eventually become resistant to existing treatments, new treatment options like TREANDA are needed to improve patient outcome," stated Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C. and TREANDA clinical investigator. "The TREANDA pivotal trial shows that it is an effective and well-tolerated chemotherapy that offers a delay in disease progression for more than nine months."

According to Dr. Lesley Russell, Executive Vice President and Chief Medical Officer, Cephalon, "We are excited about this seco
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
2. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
3. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
4. Cephalon Conference Call Invitation
5. Cephalon Reports Strong First Quarter Earnings
6. Cephalon Appoints Gerald J. Pappert as General Counsel
7. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
8. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
9. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Undocumented farmworkers are ... to use Medicaid, the federal health insurance program ... a new study from UC Davis Health System. ... of farmworker use of Medicaid, which provides coverage ... documentation status, was having children. , “Undocumented ...
(Date:2/27/2015)... Freeport, ME (PRWEB) February 27, 2015 Royal ... Freeport, ME, reports a new study that found adults who ... to develop type 2 diabetes compared to those who got ... elevated blood sugar levels. , The report is part of ... Being® ,” which Royal River Natural Foods publishes free each ...
(Date:2/27/2015)... 27, 2015 On February 24 2015, Harper’s ... Botox ,” that details the development of RT001, a ... its way through FDA trials. For those afraid of needles, ... very attractive. Of course, if the drug ultimately gets FDA ... physician’s office. (see: goo.gl/PQvQwk) , “As the article notes, the ...
(Date:2/27/2015)... Winter is here, and with it comes ... to snow and ice can be harmful on a dog’s ... The Puppy Store is ready to help pet owners know ... in the winter time. , Ice melts can lead to ... symptoms. Ingestion of ice melt products may cause depression, loss ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Victorian Hotel ... deals for couples who wanted to spend the auspicious ... opportunity to get a jump on Valentine’s Day with ... stay in one of their luxurious rooms. , ... 13, inviting guests for a mouthwatering 3 course meal ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Is Topical Botox the Next Big Thing? 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... value to patients and health-care system overall, , SUNDAY, ... at all these days without stumbling across drug advertisements ... quickly mumbled list of side effects. , If you ... before, you,re right. , The amount of money spent ...
... ... kits for life science and clinical laboratories. , ... Pleasanton, CA (PRWEB) October 4, 2009 -- Arcxis Biotechnologies ... line of nucleic acid isolation and purification kits. These sample preparation kits are optimized ...
... ... group, have won a prestigious ,Top Ten Website, award from the online intelligence experts Hitwise. ... 160+ categories. From January to June 2009 Spire Healthcare was ranked the ninth most visited ... ...
... not waiting for sunrise," says aid worker in Northern Luzon ... the next few hours , ISABELA PROVINCE, Philippines, Oct. 3 ... Isabela Province, one of the areas wracked by Typhoon Parma. ... World Vision programme manager in Northern Luzon. "We will ...
... say, , SATURDAY, Oct. 3 (HealthDay News) -- Imagine that ... of it so you take a picture of it using ... for an opinion. , Or perhaps you have heart disease ... uploads the data to your cardiologist,s computer for review. , ...
... ... the U.S., yet many breast cancer patients are not being informed about all of ... Cancer Awareness Month, Park Meadows Cosmetic Surgery invites women to become more aware about ... ...
Cached Medicine News:Health News:As TV Drug Ads Increase, So Do Concerns 2Health News:As TV Drug Ads Increase, So Do Concerns 3Health News:Arcxis Biotechnologies Announces Release of First Commercial Product for Molecular Analysis 2Health News:Spire Healthcare Win Hitwise Award 2Health News:Typhoon Parma: World Vision Launches Relief Efforts in the Philippines, Pre-positions Supplies in Taiwan 2Health News:In Health Care Today, It's Electronic All the Way 2Health News:In Health Care Today, It's Electronic All the Way 3Health News:Park Meadows Cosmetic Surgery, a Leader in Breast Reconstruction Surgery, Recognizes National Breast Cancer Awareness Month 2Health News:Park Meadows Cosmetic Surgery, a Leader in Breast Reconstruction Surgery, Recognizes National Breast Cancer Awareness Month 3
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... MARLBOROUGH, Mass. , Feb. 27, 2015  Boston ... to participate in the Barclays 2015 Annual Healthcare Conference ... . Dan Brennan , executive vice ... , vice president, Investor Relations, will participate in a ... the host analyst at approximately 1:05 p.m. ET. Following ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... 19, 2011 Agendia, an innovative ... published report highlighting the development and validation of ... online in Breast Cancer Research and Treatment ... of Agendia,s Symphony™ suite of breast cancer products, ...
... Sept. 19, 2011 Reportlinker.com announces that ... in its catalogue: South ... to 2017 http://www.reportlinker.com/p0617106/South-and-Central-America-Cardiovascular-Devices-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices ... Cardiovascular Devices Market Outlook to 2017 ...
Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3South and Central America Cardiovascular Devices Market Outlook to 2017 2South and Central America Cardiovascular Devices Market Outlook to 2017 3South and Central America Cardiovascular Devices Market Outlook to 2017 4South and Central America Cardiovascular Devices Market Outlook to 2017 5South and Central America Cardiovascular Devices Market Outlook to 2017 6South and Central America Cardiovascular Devices Market Outlook to 2017 7South and Central America Cardiovascular Devices Market Outlook to 2017 8South and Central America Cardiovascular Devices Market Outlook to 2017 9South and Central America Cardiovascular Devices Market Outlook to 2017 10South and Central America Cardiovascular Devices Market Outlook to 2017 11South and Central America Cardiovascular Devices Market Outlook to 2017 12South and Central America Cardiovascular Devices Market Outlook to 2017 13South and Central America Cardiovascular Devices Market Outlook to 2017 14South and Central America Cardiovascular Devices Market Outlook to 2017 15South and Central America Cardiovascular Devices Market Outlook to 2017 16South and Central America Cardiovascular Devices Market Outlook to 2017 17
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: